

Use of oxytocin after spontaneous onset of labor in France

Corinne Dupont, Didier Riethmuller, Catherine Deneux-Tharaux, Rémi Beranger, Anne A Chantry, Laurent Gaucher, Camille Le Ray, Chloé Barasinski, Françoise Vendittelli, Bénédicte Coulm, et al.

▶ To cite this version:

Corinne Dupont, Didier Riethmuller, Catherine Deneux-Tharaux, Rémi Beranger, Anne A Chantry, et al.. Use of oxytocin after spontaneous onset of labor in France: New guidelines by the French National College of Midwives (CNSF), in collaboration with the French National College of Gynecologists and Obstetricians (CNGOF) . 31st International Confederation of Midwives (ICM) trienal congress, Jun 2017, Toronto, France. hal-01564458

HAL Id: hal-01564458 https://univ-rennes.hal.science/hal-01564458

Submitted on 18 Jul 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.





Use of oxytocin after spontaneous onset of labor in France

Collège National des Gynécologues et Obstétriciens Français

New guidelines by the French National College of Midwives (CNSF), in collaboration with the French National College of Gynecologists and Obstetricians (CNGOF)

Corinne Dupont^{6, 1, 2}, Didier Riethmuller¹¹, Catherine Deneux-Tharaux⁵, <u>Rémi Beranger</u>⁴, Anne A. Chantry^{5, 13}, Laurent Gaucher^{1, 2}, Camille Le Ray⁸, Chloé Barasinski⁹, Françoise Vendittelli⁹, Bénédicte Coulm⁵, Véronique Tessier³, Anne Rousseau¹², Antoine Burguet¹⁰, Catherine Fischer⁸, Camille Guillou¹⁴, Fabienne Leroy¹⁵, Coralie Chiesa-Dubruille⁵, Emmanelle Phan¹⁶, Anne Evrard¹⁶, Marion Carayol⁷

Introduction

- France had no clinical guideline for oxytocin usage during spontaneous labor
- 58% of French women in spontaneous labor received oxytocin (2010).
- Oxytocin is probably overused due to obsolete definition of normal labor and misusage
- Oxytocin usage might have serious consequence for mothers and newborns

Objectives

- To define normal and abnormal labor
- To specify the indications, dosage, procedures and effects of oxytocin administration
- To describe the adverse maternal and perinatal effects associated with it

1. Normal and abnormal labor


1st stage of labor (one latent and one active phases)

- No labor dystocia during the latent phase
- Active phase start at **5-6cm** of dilation
- Dilation speed should be considered abnormal if
 - slower than 1 cm/4 h before 7cm
 - slower than 1 cm / 2h after 7cm

H₂N H₂N CH₃ H₄N CH₄N C

2nd stage of labor (one descent and one expulsion phases)

- The maximum duration of the descent phase of the second stage of labor cannot be determined from the literature
- But the risk-benefit balance becomes less favorable after 3 hours



Reference: Dupont C et al. Oxytocin administration during spontaneous labor: Guidelines for clinical practice. Guidelines short text. J Gynecol Obstet Hum Reprod. 2017 May 2 (online).

2. Oxytocin administration

- Oxytocin should be administered at ruptured membrane in case of labor dystocia or in case of 2nd stage prolonged beyond 2 hours
- Oxytocin should be administered at the minimum effective dose
- Uterine response and fetal heart rate must be taken into account
- Amniotomy should be performed 1h before oxytocin administration
- No routine amniotomy or oxytocin before 5cm of dilation
- Epidural is not a reason for routine oxytocin administration
- Oxytocin administration should be considered as indicator for monitoring quality of care in delivery room

3. Procedure for administration

- Intravenous, using dose flow-rate control equipment
- Oxytocin should be administered at an **initial dose of 2mU/min**
- The oxytocin dose should be **increase by 2mU/min**, waiting at least **30min** between each increase, until cervical modification or 5 effective uterine contractions / 10min
- Dose should not exceed 20mU/min

4. Maternal and fetal adverse effects

- Oxytocin administration is associated with increased risk of uterine hyperactivity, post-partum hemorrhage, rupture of unscarred uterus, and neonatal acidosis
- We observed no evidence of causal relation with pain, women dissatisfaction with their birth experience, neonatal morbi-mortality (industrialized countries), hyponatremia, neonatal jaundice, or autism spectrum disorder.
- Oxytocin perfusion and the condition of its use should be analyzed during morbidity and mortality conferences

